Not Making Headlines: Japan’s Kowa Company Finds Ivermectin is Effective Against Omicron and Other COVID-19 Variants in Phase 3 Trial
Kowa Company Ltd, a Japanese company specializing in trading and sales of medicines and medical equipment, announced on Monday that Ivermectin has an “antiviral effect” against Omicron and other COVID-19 variants as Phase III clinical trials continue, Reuters reported.
The clinical trial found Ivermectin has “an antiviral effect” against the variant, Kowa said without providing additional information.
The study has been supported financially by the Japan Agency for Medical Research and Development and Kitasato Institute.
The study started last September 16, 2020 and the planned end date is March 31, 2022. The study is titled, “Placebo-controlled randomized double-blind (evaluators, patients) multi-facility joint parallel-group comparison trial to examine the efficacy and safety of Ivermectin for COVID-19 patients.”
Here is a background on the study updated last November 7,
